FGFR2/3-IN-3
FGFR2/3-IN-3 is a dual-target FGFR2/3 inhibitor with IC50s of 2.7 nM (TEL-FGFR2) and 3.9 nM (TEL-FGFR3), respectively. FGFR2/3-IN-3 has effective activity against both wild-type and mutant FGFR3. FGFR2/3-IN-3 has low CYP3A4 inhibitory effect and hERG toxicity. FGFR2/3-IN-3 improves the imbalance between chondrocyte proliferation and differentiation and promotes bone growth by inhibiting the signaling pathway mediated by mutant FGFR3. FGFR2/3-IN-3 shows a growth-promoting effect in a dwarfism mouse model and has the potential to study bone development disorder-related diseases such as achondroplasia (ACH).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3069945-78-1
- 화학식: C28H27Cl2FN6O2
- 분자량:569.46
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
CYP2C9 3.9 μM (IC50) |
CYP2D6 5.0 μM (IC50) |
CYP3A4M 7.2 μM (IC50) |
FGFR3 3.9 nM (IC50) |
FGFR2 2.7 nM (IC50) |
In Vitro
FGFR2/3-IN-3 (compound 23) exhibits potent inhibitory activity against both wild-type (IC50 = 3.2 nM) and V555M mutant (IC50 = 0.5 nM) FGFR3, as well as TEL-FGFR1 (IC50 = 29.4 nM) and TEL-FGFR4 (IC50 = 29 nM)[1].
FGFR2/3-IN-3 exhibits inhibiting activity on the common FGFR3G380R (IC50 = 7.0 nM), FGFR3WT (IC50 = 3.9 nM), FGFR3V555L (IC50 = 1.7 nM), FGFR3L608V (IC50 = 10.0 nM), mutation in ACH in TEL-FGFR3 Mutant Ba/F3 Cell Lines[1].
FGFR2/3-IN-3 inhibits the growth of RT-112/84 cell (IC50 = 1.3 nM) in FGFR3-driven tumor cells[1].
FGFR2/3-IN-3 demonstrates slightly stronger inhibitory activity against the CYP subtypes 2C9 (IC50 = 3.9 μM) and 2D6 (IC50 = 5.0 μM) compared to the 3A4 subtype[1].
FGFR2/3-IN-3 (0.2 μM, 1 μM) rescues FGF-induced growth retardation in an ex vivo fetal mouse femur culture model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUClast | CL | F |
|---|---|---|---|---|---|---|---|---|
| Mice | 0.5 mg/kg | s.c. | 2.3 h | 1.3 h | 49.2 ng/mL | 228 ng·h/mL | / | / |
| Mice | 1 mg/kg | s.c. | 2.0 h | 1.7 h | 100 ng/mL | 449 ng·h/mL | / | / |
| Mice | 2 mg/kg | s.c. | 2.8 h | 2.7 h | 171 ng/mL | 1127 ng·h/mL | / | / |
| Rat | 1 mg/kg | i.v. | / | / | / | 965 ng·h/mL | 18 mL/min/kg | / |
| Rat | 10 mg/kg | p.o. | / | 8.0 h | 517 ng/mL | 6909 ng·h/mL | / | 52 % |
| Rat | 2 mg/kg | p.o. | 4.3 h | 5.7 h | 27.9 ng/mL | 209 ng·h/mL | / | / |
| Rat | 20 mg/kg | p.o. | / | 8.0 h | 1273 ng/mL | 18373 ng·h/mL | / | 98.6 % |
| Rat | 5 mg/kg | p.o. | / | 6.7 h | 211 ng/mL | 2424 ng·h/mL | / | 52 % |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fgfr3Y367C/+ mouse model of ACH[1]
-
Dosage:0.5 mg/kg, 2 mg/kg
-
Administration:s.c., 14 days
-
Result:Enhanced overall body growth promotion as well as the growth increase for tail, tibia, and femur.
Chemical Information
-
CAS No. 3069945-78-1
-
분자량 569.46
-
화학식 C28H27Cl2FN6O2
-
SMILES
CC(C)(CN1N=C(C(C2=NC=C(C=C2F)C3=NNC4=C3C=C(C(C)=C4)O[C@H](C)C5=C(C=NC=C5Cl)Cl)=C1)C)O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)